Wealthspire Advisors (New York)’s Catalyst Pharmaceutical CPRX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$570K	Sell	18,142 -16,217	-47%	-$479K	﹤0.01%	751
2026 Q1	$851K	Sell	34,359 -2,801	-8%	-$66.7K	0.01%	441
2025 Q4	$867K	Buy	37,160 +317	+0.9%	+$7.06K	0.01%	460
2025 Q3	$726K	Sell	36,843 -36	-0.1%	-$740	﹤0.01%	457
2025 Q2	$800K	Buy	36,879 +2,445	+7%	+$57.7K	﹤0.01%	430
2025 Q1	$835K	Buy	34,434 +79	+0.2%	+$1.78K	0.01%	421
2024 Q4	$717K	Buy	34,355 +84	+0.2%	+$1.8K	0.01%	433
2024 Q3	$681K	Sell	34,271 -2,021	-6%	-$37.5K	0.01%	437
2024 Q2	$562K	Hold	36,292	–	–	0.01%	408
2024 Q1	$578K	Hold	36,292	–	–	0.01%	400
2023 Q4	$610K	Hold	36,292	–	–	0.01%	389
2023 Q3	$424K	Sell	36,292 -2,978	-8%	-$39.8K	0.01%	421
2023 Q2	$528K	Hold	39,270	–	–	0.01%	349
2023 Q1	$651K	Buy	39,270 +4,614	+13%	+$76.1K	0.01%	314
2022 Q4	$645K	Buy	34,656 +386	+1%	+$5.94K	0.01%	342
2022 Q3	$440K	Sell	34,270 -48,500	-59%	-$575K	0.01%	355
2022 Q2	$580K	Hold	82,770	–	–	0.01%	294
2022 Q1	$686K	Sell	82,770 -55,000	-40%	-$389K	0.02%	227
2021 Q4	$933K	Sell	137,770 -200,000	-59%	-$1.32M	0.02%	238
2021 Q3	$1.79M	Hold	337,770	–	–	0.04%	177
2021 Q2	$1.94M	Hold	337,770	–	–	0.05%	114
2021 Q1	$1.56M	Hold	337,770	–	–	0.04%	203
2020 Q4	$1.13M	Hold	337,770	–	–	0.03%	195
2020 Q3	$1M	Hold	337,770	–	–	0.06%	124
2020 Q2	$1.56M	Hold	337,770	–	–	0.11%	80
2020 Q1	$1.3M	Buy	+337,770	New	+$1.39M	0.05%	165

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wealthspire Advisors (New York)'s CPRX Position: Q2 2026 in Review

Wealthspire Advisors (New York) reduced its Catalyst Pharmaceutical (CPRX) stake by 47% in Q2 2026, selling an estimated $479K and leaving 18,142 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #751.

Wealthspire Advisors (New York) first reported a position in CPRX in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.94M in Q2 2021. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Wealthspire Advisors (New York) held 18,142 shares of Catalyst Pharmaceutical worth $570K as of Q2 2026.
Wealthspire Advisors (New York) sold 16,217 Catalyst Pharmaceutical shares in Q2 2026, an estimated $479K.
Catalyst Pharmaceutical made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #751 holding.
Wealthspire Advisors (New York) first reported a position in Catalyst Pharmaceutical in Q1 2020 and has held it in 26 quarters since.
Wealthspire Advisors (New York)'s Catalyst Pharmaceutical position peaked at $1.94M in Q2 2021.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.